This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Stopped early · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of pembrolizumab as a single agent and the dynamic of the tumor microenvironment changes on treatment.

Key facts

Study ID

NCT03968419

Run by

Novartis Pharmaceuticals

People needed

88

Starts

2019-11-05

Expected to finish

2022-08-15

Last updated by the study team

2024-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Oncology Hematology — La Jolla, California, United States
• University of Kansas Medical Center Neurology Dept. — Kansas City, Kansas, United States
• SUNY - Upstate Medical University — Syracuse, New York, United States
• Methodist Hospital / Methodist Cancer Center — Houston, Texas, United States
• Novartis Investigative Site — Brussels, Belgium
• Novartis Investigative Site — Montreal, Quebec, Canada
• Novartis Investigative Site — Montpellier, Herault, France
• Novartis Investigative Site — Bron, France
• Novartis Investigative Site — Paris, France
• Novartis Investigative Site — Bad Berka, Germany
• Novartis Investigative Site — Cologne, Germany
• Novartis Investigative Site — Giessen, Germany
• Novartis Investigative Site — Halle, Germany
• Novartis Investigative Site — Thessaloniki, Greece
• Novartis Investigative Site — Kashiwa, Chiba, Japan
• Novartis Investigative Site — 's-Hertogenbosch, Netherlands
• Novartis Investigative Site — Breda, Netherlands
• Novartis Investigative Site — Maastricht, Netherlands
• Novartis Investigative Site — Omsk, Russia
• Novartis Investigative Site — Saint Petersburg, Russia
• Novartis Investigative Site — Saint Petersburg, Russia
• Novartis Investigative Site — Jaén, Andalusia, Spain
• Novartis Investigative Site — Oviedo, Principality of Asturias, Spain
• Novartis Investigative Site — Madrid, Spain
• Novartis Investigative Site — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.